RHHVF

OTC Markets OTCQX

Roche Holding AG

Healthcare

Drug Manufacturers - General

Switzerland

470.06USD

-14.22 (-2.94%)

Market Cap: 374.53B USD

Revenue and Net Income

Values in CHF

Income Statement

Values in CHF

Financial item	TTMJun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Total Revenue	62.96B	63.36B	62.40B	60.44B	65.81B
Cost of Revenue	16.62B	16.64B	16.28B	16.36B	19.74B
Gross Profit	46.34B	46.71B	46.11B	44.08B	46.08B
Operating Expense	28.52B	28.23B	32.70B	28.69B	28.60B
Operating Income	17.82B	18.48B	13.42B	15.39B	17.48B
Net Non Operating Interest Income Expense	-1.13B	-1.14B	-1.15B	-814.00M	-673.00M
Pretax Income	16.36B	16.97B	11.79B	14.08B	16.33B
Tax Provision	3.07B	3.17B	2.61B	1.72B	2.80B
Net Income Common Stockholders	12.34B	12.88B	8.28B	11.50B	12.42B
Average Dilution Earnings	0.00	0.00	0.00	0.00	-1000000.00
Diluted NI Available to Com Stockholders	12.34B	12.88B	8.28B	11.50B	12.42B
Basic EPS	15.50	16.18	10.39	14.40	15.52
Diluted EPS	15.33	16.04	10.31	14.31	15.37
Basic Average Shares	796.00M	796.00M	797.00M	799.00M	800.00M
Diluted Average Shares	805.00M	803.00M	802.00M	804.00M	808.00M
Total Operating Income as Reported	17.82B	18.48B	13.42B	15.39B	17.48B
Total Expenses	45.14B	44.88B	48.98B	45.05B	48.34B
Net Income from Continuing & Discontinued Operation	12.34B	12.88B	8.28B	11.50B	12.42B
Normalized Income	12.68B	13.29B	8.36B	11.60B	12.97B
Interest Income	177.00M	203.00M	260.00M	195.00M	67.00M
Interest Expense	1.29B	1.35B	1.40B	997.00M	690.00M
Net Interest Income	-1.13B	-1.14B	-1.15B	-814.00M	-673.00M
EBIT	17.65B	18.32B	13.20B	15.08B	17.02B
EBITDA	21.05B	21.70B	16.62B	18.54B	20.86B
Reconciled Cost of Revenue	16.62B	16.64B	16.28B	16.36B	19.74B
Reconciled Depreciation	3.40B	3.39B	3.42B	3.46B	3.84B
Net Income from Continuing Operation Net Minority Interest	12.34B	12.88B	8.28B	11.50B	12.42B
Total Unusual Items Excluding Goodwill	-423.00M	-507.00M	-106.00M	-117.00M	-665.00M
Total Unusual Items	-423.00M	-507.00M	-106.00M	-117.00M	-665.00M
Normalized EBITDA	21.47B	22.21B	16.73B	18.66B	21.53B
Tax Rate for Calcs	0.19	0.19	0.22	0.12	0.17
Tax Effect of Unusual Items	-79.28M	-94.81M	-23.43M	-14.27M	-113.72M

Key Statistics

Valuation

Market Cap (USD)374.53B

Market Cap (Local)374.53B

P/E (TTM)25.10

P/S (TTM)4.92

MC/EBITDA14.72

Volume & Shares

Last Volume1900.00

Avg Vol (10D)1533.00

Avg Vol (30D)714.00

Avg Vol (90D)4834.00

Shares Outstanding796.77M

Growth Indicators

Revenue TTM/Ann0.99

Net Income TTM/Ann0.96

EBITDA TTM/Ann0.97

Gross Profit TTM/Ann0.99

Operating Inc TTM/Ann0.96

Currency & Exchange

Trading CurrencyUSD

Financial CurrencyCHF

Trading/USD Rate1.00

Financial/USD Rate1.21

ExchangeOTC Markets OTCQX

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others diagnostic instruments and digital health solutions. Roche Holding AG has a collaboration agreement with Excalipoint Therapeutics to evaluate EXP011 in DLL3-expressing solid tumors. The company was founded in 1896 and is based in Basel, Switzerland.